Zacks Small Cap Issues Optimistic Estimate for TNXP Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Zacks Small Cap lifted their Q2 2025 EPS estimates for Tonix Pharmaceuticals in a research report issued on Wednesday, May 28th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($10.73) per share for the quarter, up from their previous estimate of ($12.49). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' Q3 2025 earnings at ($3.65) EPS, Q4 2025 earnings at ($4.40) EPS, FY2025 earnings at ($13.96) EPS, FY2026 earnings at ($7.48) EPS and FY2027 earnings at ($0.30) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $0.39. The firm had revenue of $2.43 million during the quarter, compared to analyst estimates of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%.

TNXP has been the subject of several other research reports. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Noble Financial reiterated an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Trading Down 5.3%

Shares of NASDAQ TNXP traded down $2.22 during midday trading on Friday, reaching $39.80. The company had a trading volume of 1,571,151 shares, compared to its average volume of 891,944. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $550.40. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm's fifty day moving average price is $21.50 and its 200-day moving average price is $22.14. The stock has a market cap of $291.54 million, a PE ratio of -0.01 and a beta of 1.63.

Insider Activity

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 4,000 shares of the stock in a transaction on Thursday, May 15th. The stock was acquired at an average price of $21.55 per share, with a total value of $86,200.00. Following the transaction, the chief executive officer now directly owns 4,005 shares of the company's stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.03% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TNXP. Commonwealth Equity Services LLC bought a new position in Tonix Pharmaceuticals in the 4th quarter worth $40,000. Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals in the fourth quarter worth about $66,000. PFG Investments LLC bought a new position in Tonix Pharmaceuticals in the fourth quarter worth about $72,000. Northern Trust Corp bought a new position in Tonix Pharmaceuticals in the fourth quarter worth about $162,000. Finally, IFP Advisors Inc bought a new position in shares of Tonix Pharmaceuticals in the 1st quarter worth approximately $179,000. 82.26% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.